About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...
Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience severe infections compared with ...
A new bone marrow test can help doctors predict risk of leukemia relapse The test might double survival rates by predicting a relapse up to three months earlier than standard care The test looks for ...
Open-Source Hybrid Large Language Model Integrated System for Extraction of Breast Cancer Treatment Pathway From Free-Text Clinical Notes The diagnosis of chronic lymphocytic leukemia (CLL) is often ...
Two distinct subtypes, U-CLL C1 and U-CLL C2, were identified within IGHV-unmutated chronic lymphocytic leukemia, showing ...
Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different types of leukemia. Both conditions affect white blood cells. CML affects a type of white blood cell called ...
BOZEMAN, MT, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Alercell is all set to launch LENA Q51(R) in January 2023. A leukemia diagnostic test based on sequencing DNA will detect up to 51 Genes mutations in ...
Imbruvica plus venetoclax significantly extends PFS in untreated CLL patients compared to chlorambucil plus Gazyva, with 52 months versus 31 months. The combination therapy shows durable efficacy and ...
The Test Before Treat campaign highlights how a patient’s genetic profile can change over time and encourages the use of a blood test to identify mutations to provide important insights into disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results